Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2512345...1020...Last »

Gates backs gene technologies in fight to end malaria

Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.

Read More »

Eli Lilly Shows Off More Verzenio Data at AACR

Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.

Read More »

CRISPR Therapeutics Plans to Treat First Patients for Beta Thalassemia in Europe

CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.

Read More »

AbbVie’s Arthritis Drug Dazzles in Phase III Trial

AbbVie announced positive top-line data from the company’s Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate-to-severe rheumatoid arthritis.

Read More »

Incyte, Merck melanoma combo therapy fails study

An independent committee concluded that Inctye Corp.’s drug for a type of skin cancer in combination with Merck & Co.’s Keytruda failed to meet the main goal in a late-stage study.

Read More »

Rigel’s Tavalisse Fails Kidney Disease Trial

As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.

Read More »

Ablynx Lupus Drug Fails Again in Mid-Stage Trial

Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

Read More »

Protagonist Therapeutics Discontinues Phase IIb Ulcerative Colitis Study

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Read More »

Pfizer’s Chantix fails study in adolescent smokers

Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.

Read More »

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.

Read More »

Eylea Shows Promising Data for Diabetic Retinopathy

Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

Read More »

Heron Therapeutics Soars on Positive Phase III Results

Heron Therapeutics said the company’s late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain.

Read More »

Auris Medical Fails Again in Phase III Trial

Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.

Read More »

Eisai, Merck Enter Strategic Oncology Collaboration

Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.

Read More »

Esperion cholesterol drug succeeds in late-stage study

Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.

Read More »

Novo’s diabetes pill impresses in first big study

The world’s largest diabetes drugmaker, Novo Nordisk, presented the first successful data from a large final-stage study of a pill the company hopes will transform the diabetes market.

Read More »

AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids

AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.

Read More »

Aimmune’s peanut allergy drug meets main goal

U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Read More »

Eli Lilly and Hanmi Shutter a Failed Phase II RA Trial

Eli Lilly and its Korean collaborative partner Hanmi Pharmaceutical stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined.

Read More »

Eisai’s Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet

Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.

Read More »

Page 1 of 2512345...1020...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation